[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-346360-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-346360-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","emerging-immunotherapeutic-strategies-for-malignant-serous-effusions-current-evidence-and-future-directions","Emerging immunotherapeutic strategies for malignant serous effusions: current evidence and future directions","","Malignant serous effusions arise when advanced tumors invade serous cavities, creating implantation metastasis and fluid accumulation that contains cancer cells. This complication is common across lung, breast, gastric, and ovarian cancers, signals poor prognosis, and limits survival to about 3–15 months. Conventional drainage and intrapleural chemotherapy show restricted efficacy and tolerability because they do not address immune suppression and tumor heterogeneity. Immunotherapy is reviewed as a strategy against drug-resistant disease, including preclinical STING-activating LNP-CDN and emerging local CAR-T approaches, while acknowledging evidence mostly comes from models, small cohorts, and early-phase trials.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/emerging-immunotherapeutic-strategies-for-malignant-serous-effusions-current-evidence-and-future-directions/346360/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/emerging-immunotherapeutic-strategies-for-malignant-serous-effusions-current-evidence-and-future-directions/346360.png","ImageObject",300,407,{"name":42,"@type":43},"Himbo","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What are malignant serous effusions and why are they clinically important?","Question",{"text":63,"@type":64},"Malignant serous effusions are fluid accumulations in pleural, peritoneal, or pericardial cavities caused by malignant tumor invasion. They reflect advanced disease, correlate with specific symptoms by cavity, and indicate poor prognosis and reduced quality of life.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Why do traditional treatments have limited durable control in malignant effusions?",{"text":68,"@type":64},"Drainage and intrapleural chemotherapy are limited because they do not target the immunosuppressive tumor microenvironment and tumor heterogeneity that drive effusion recurrence.",{"name":70,"@type":61,"acceptedAnswer":71},"Which immunotherapeutic approaches are highlighted as emerging strategies?",{"text":72,"@type":64},"The review highlights STING-activating liposomal nanoparticles containing cyclic dinucleotides (LNP-CDN) and local infusion of CAR-T cells. Preclinical data suggest improved immune responses, while early clinical reports show preliminary survival benefits requiring further large-scale validation.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},346360,1790679169,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","TYPE Review  \nPUBLISHED 21 January 2026 DOI 10.3389/fonc.2026.1757825  \nOPEN ACCESS  \nEDITED BY  \nAmorette Barber,  \nLongwood University, United States  \nREVIEWED BY  \nNazila Bahmaie,  \nAnkara Yıldırım Beyazıt University, Türkiye Samson Peter Mvandal,  \nMuhimbili National Hospital, Tanzania  \n*CORRESPONDENCE  \nYongsheng Wang  \n [wangys@scu.edu.cn](wangys@scu.edu.cn)  \n†These authors have contributed equally to this work and share ﬁrst authorship  \nRECEIVED 01 December 2025  \nREVISED 02 January 2026  \nACCEPTED 02 January 2026  \nPUBLISHED 21 January 2026  \nCITATION  \nHe W, He X, Qiao Z and Wang Y (2026) Emerging immunotherapeutic strategies for malignant serous effusions: current evidence and future directions.  \nFront. Oncol. 16:1757825 .  \ndoi: 10.3389/fonc.2026.1757825  \nCOPYRIGHT  \n© 2026 He, He, Qiao and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nEmerging immunotherapeutic strategies for malignant serous effusions: current evidence and future directions  \nWeimin He 1†, Xia He 2†, Zhi Qiao 3 and Yongsheng Wang 1,2*  \n1 Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China, 2Clinical Trial Center, National Medical Products Administration Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, West China Hospital, Sichuan University, Chengdu, China, 3 Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China  \nThe invasion of serous cavities by malignant tumors, leading to implantation metastasis, is a hallmark of advanced cancer, causing pathological buildup of ﬂuid (malignant effusions) containing cancerous cells, which indicates advanced disease and poor prognosis. The primary cancers involved include lung, breast, gastric, and ovarian cancers, affecting a large patient population with a high incidence rate. Because effective treatment options are limited in clinical practice, patients with malignant effusion, based on the severity, typically survive only 3 to 15 months. Traditional therapies, such as local drainage combined with intrapleural chemotherapy, have limited efﬁcacy and tolerability. Immunotherapy has emerged as a potential approach for drugresistant malignant tumors, driven by deeper insights into resistance mechanisms, tumor heterogeneity, and the immune microenvironment of malignant effusions. Preclinical studies show that liposomal nanoparticles containing cyclic dinucleotides (LNP-CDN) can activate the STING (Stimulatorof Interferon Genes) signaling pathway; local injection into mouse pleural cavities enhances the “cold” tumor immune response and improves tumor treatment outcomes. In early-phase clinical studies and small cohorts, local infusion ofchimeric antigen receptor T cells (CAR-T) showed preliminary survival beneﬁts over ﬁrst-line standard treatments, with good safety proﬁles and high tolerable doses, but these ﬁndings require further validation in large-scale trials. This article reviews tumor serosal metastasis epidemiology, summarizes current treatment options, and discusses the development direction of clinical strategies considering the immune microenvironment of malignant effusions, with a focus on advancements in cell immunotherapy. Despite the therapeutic potential of immunotherapy, its efﬁcacy in malignant effusions, while measurable, remains to be fully optimized. A key limitation is that most evidence presented derives from preclinical models, small patient cohorts, or phase I/II trials, and deﬁnitive clinical efﬁcacy remains unconﬁr","cbCaij6o2uEWJh5o","https://ap.wps.com/l/cbCaij6o2uEWJh5o","pdf",886508,11,"English","# Introduction\n## Epidemiology and clinical significance of malignant serous effusions\n## Mechanisms driving treatment resistance and immune suppression\n# Current and emerging immunotherapeutic strategies\n## STING pathway activation approaches\n## Cell immunotherapy, including CAR-T\n# Future directions and evidence gaps\n## Translational challenges and needs for larger clinical validation","[{\"question\":\"What are malignant serous effusions and why are they clinically important?\",\"answer\":\"Malignant serous effusions are fluid accumulations in pleural, peritoneal, or pericardial cavities caused by malignant tumor invasion. They reflect advanced disease, correlate with specific symptoms by cavity, and indicate poor prognosis and reduced quality of life.\"},{\"question\":\"Why do traditional treatments have limited durable control in malignant effusions?\",\"answer\":\"Drainage and intrapleural chemotherapy are limited because they do not target the immunosuppressive tumor microenvironment and tumor heterogeneity that drive effusion recurrence.\"},{\"question\":\"Which immunotherapeutic approaches are highlighted as emerging strategies?\",\"answer\":\"The review highlights STING-activating liposomal nanoparticles containing cyclic dinucleotides (LNP-CDN) and local infusion of CAR-T cells. Preclinical data suggest improved immune responses, while early clinical reports show preliminary survival benefits requiring further large-scale validation.\"}]","Emerging immunotherapeutic strategies for malignant serous effusions: current evidence and future directions | PDF",1790061110,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2376f73762365142233a9b8bb938a2eb.webp",983,1389,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c2946f3ca9c6efeaf7556a559a9cef65.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d0f34d3f7373c0439571976357f72edb.webp",981,1386,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cd9750f781b919ef5aea22741e06bbf0.webp",980,1385]